Niagen Bioscience (NAGE) AI Stock Analysis

• Market Cap: $721.53M
• Dividend Yield: N/A
• Average Volume (3M): 1.13M
• Price to Earnings (P/E): 54.4
• Beta (1Y): 1.04
• Revenue Growth: 29.77%
• EPS Growth: N/A
• Country: US
• Employees: 104
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.06
• Shares Outstanding: 78,769,660
• 10 Day Avg. Volume: 1,102,031
• 30 Day Avg. Volume: 1,132,102
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $15.30
• Price Target Upside: 58.71% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 70 Outperform
• Price Target: $10.50 ▲(8.92% Upside)

Niagen Bioscience's strong financial performance and positive earnings call sentiment are major strengths, driving the overall score. However, technical analysis indicates bearish momentum, and high valuation metrics suggest caution. The company's ability to navigate regulatory challenges and maintain growth will be key to future performance.

Positive Factors

Clinical Study Results

Niagen Bioscience announced positive clinical study results that were recently published in the peer-reviewed journal Aging Cell.

Revenue Growth

Revenue outperforms expectations, with Niagen Bioscience reporting $30.5M in top-line revenue, exceeding forecasted figures.

Strategic Expansion

Niagen IV broadens U.S. clinic footprint, poised for further rapid market uptake.

Negative Factors

Clinical Trials

Key clinical study in Parkinson's disease remains slated to potentially yield top-line results in 1H25, which could significantly impact the company's prospects.

Market Valuation

There is still little consideration in valuing NAGE's opportunity in rare and orphaned diseases, which is seen as a major positive for NAGE.

Niagen Bioscience Business Overview & Revenue Model

Company Description

Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.

How the Company Makes Money

Niagen Bioscience generates revenue through multiple streams, primarily by selling its proprietary NAD+ boosting supplements directly to consumers and through partnerships with health and wellness retailers. The company also engages in licensing agreements with other firms to distribute its patented technology and formulations, creating a steady income from royalties. Additionally, Niagen invests in research collaborations with academic institutions and pharmaceutical companies, which can provide funding and resources to further develop its product lines. The combination of direct sales, licensing fees, and research partnerships contributes significantly to Niagen's earnings.

Niagen Bioscience Financial Statement Overview

Summary

Chromadex shows strong profitability improvements with a positive net income turnaround and excellent cash flow growth. However, declining revenue presents a risk to sustained growth. The balance sheet remains robust with low leverage.

Income Statement

Chromadex shows a substantial recovery in net income from a loss of $4.94M in 2023 to a profit of $8.55M in 2024, indicating strong profitability improvements. However, revenue decreased from $83.57M in 2023 to $61.59M in 2024, resulting in a negative revenue growth rate, which is a concern. The company achieved a positive EBIT margin, shifting from a negative margin in the previous year, reflecting improved operational efficiency.

Balance Sheet

The company has a strong equity position with a debt-to-equity ratio of 0.06, indicating low leverage. The equity ratio increased to 67.5% in 2024, up from 51.8% in 2023, highlighting a solid capital structure. Return on equity improved significantly with positive net income, reflecting enhanced shareholder value. The balance sheet is robust, but a reduction in total revenue could impact future stability.

Cash Flow

Chromadex's free cash flow increased significantly from $6.97M in 2023 to $11.95M in 2024, showcasing strong cash generation capabilities. The operating cash flow to net income ratio is healthy, indicating efficient conversion of income into cash. Despite a decrease in investing cash flow, the strong free cash flow growth signals good financial health.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	99.60M	83.57M	72.05M	67.45M	59.26M
Gross Profit	61.59M	50.78M	42.80M	41.49M	35.27M
EBITDA	9.21M	-3.89M	-16.74M	-25.45M	-18.34M
Net Income	8.55M	-4.94M	-16.54M	-27.13M	-19.93M
Balance Sheet
Total Assets	68.28M	54.96M	54.06M	57.84M	38.36M
Cash, Cash Equivalents and Short-Term Investments	44.51M	27.17M	20.29M	28.02M	16.50M
Total Debt	2.65M	3.28M	4.26M	4.70M	1.64M
Total Liabilities	22.18M	26.51M	25.39M	26.11M	21.93M
Stockholders Equity	46.09M	28.46M	28.67M	31.73M	16.42M
Cash Flow
Free Cash Flow	11.95M	6.97M	-15.43M	-24.57M	-10.74M
Operating Cash Flow	12.11M	7.12M	-15.10M	-24.16M	-10.60M
Investing Cash Flow	-143.00K	-143.00K	-334.00K	-409.00K	-165.00K
Financing Cash Flow	5.37M	-90.00K	7.65M	36.09M	8.65M

Niagen Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAGE, the sentiment is Negative. The current price of 9.64 is below the 20-day moving average (MA) of 10.16, below the 50-day MA of 11.72, and above the 200-day MA of 7.84, indicating a neutral trend. The MACD of -0.74 indicates Positive momentum. The RSI at 35.89 is Neutral, neither overbought nor oversold. The STOCH value of 42.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAGE.

Niagen Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NAGE	70 Outperform	$721.53M	54.43	33.47%	―	29.77%	―
BCYC	51 Neutral	$543.93M	―	-37.13%	―	-38.14%	29.69%
Sector *	51 Neutral	$7.39B	0.40	-62.86%	2.37%	15.56%	-1.99%
SVA	50 Neutral	$460.27M	―	-1.44%	―	1.98%	63.69%
MRVI	49 Neutral	$595.90M	―	-45.75%	―	-11.76%	-15.82%
OPT	39 Underperform	$480.98M	―		―	-25.10%	-7.06%
SANA	33 Underperform	$960.87M	―	-71.44%	―	―	19.94%

Niagen Bioscience Corporate Events

Niagen Bioscience Reports Strong Q2 Sales Growth

On August 6, 2025, Niagen Bioscience reported a 37% increase in net sales to $31.1 million for the second quarter of 2025, with a net income of $3.6 million. The company also raised its full-year revenue outlook, expecting growth between 22% and 27%, driven by strong sales of Tru Niagen® and Niagen® ingredients. Recent operational highlights include the completion of the Phase III NOPARK trial for Parkinson’s disease and a partnership with Haukeland University Hospital. The company also expanded its presence in luxury hospitality and wellness clinics, reflecting its strategic focus on growth and innovation in the NAD+ market.

The most recent analyst rating on (NAGE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.

Niagen Bioscience Subsidiary Signs Supply Agreement

On July 25, 2025, ChromaDex, Inc., a subsidiary of Niagen Bioscience, signed a Supply Agreement with W. R. Grace & Co.-Conn, effective April 1, 2025, for the exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL). The agreement, which runs until April 30, 2029, includes provisions for automatic renewal and requires ChromaDex to purchase a minimum quantity of NRCL annually. The agreement also outlines a potential future License Agreement for ChromaDex to manufacture NRCL, though its execution is not guaranteed.

The most recent analyst rating on (NAGE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.

Niagen Bioscience Approves Equity Plan Amendment

At the Annual Meeting of Stockholders on June 24, 2025, Niagen Bioscience‘s shareholders approved an amendment to the 2017 Equity Incentive Plan, increasing the available shares by 4.75 million. Additionally, the Employee Stock Purchase Plan was approved, allowing employees to purchase shares at a discounted rate. These decisions are expected to enhance employee engagement and align stakeholder interests with the company’s growth objectives.

The most recent analyst rating on (NAGE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.

Niagen Bioscience Reports Strong Q1 2025 Financial Results

On May 7, 2025, Niagen Bioscience, Inc. reported its financial results for the first quarter of 2025, revealing a significant year-over-year increase in net sales by 38% to $30.5 million, driven by strong demand for its Tru Niagen® and Niagen® ingredient products. The company achieved a gross margin of 63.4% and net income of $5.1 million, marking a substantial improvement from the previous year. Additionally, Niagen Bioscience announced an increased full-year outlook for 2025, expecting net sales growth between 20% and 25%, and highlighted its strategic rebranding and expansion of its NAD+ precursor patent portfolio, reinforcing its leadership in the healthy aging sector.